59 studies found for:    SGN-35
Show Display Options
Rank Status Study
1 Recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
2 Active, not recruiting Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: brentuximab vedotin (SGN-35);   Drug: Brentuximab Vedotin (SGN-35)
3 Terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-35;   Drug: gemcitabine
4 Active, not recruiting A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin;   Drug: placebo
5 Completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Conditions: Lymphoma, Non-Hodgkin;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: SGN-35
6 Recruiting Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Mocetinostat  Plus Brentuximab Vedotin
7 Completed Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
8 Active, not recruiting
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
9 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole
10 Recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
11 Not yet recruiting A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Doxorubicin Hydrochloride;   Drug: Vinblastine;   Drug: Dacarbazine
12 Recruiting Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Condition: Germ Cell Cancer
Intervention: Drug: Brentuximab Vedotin
13 Recruiting A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Condition: Primary Mediastinal Large B-cell Lymphoma.
Intervention: Drug: Brentuximab Vedotin
14 Active, not recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Conditions: Lymphoma, Non-Hodgkin;   Cutaneous Lymphoma;   Cutaneous T Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Brentuximab vedotin
15 Completed
Has Results
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Condition: Disease, Hodgkin
Intervention: Drug: brentuximab vedotin
16 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
17 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Conditions: Adult Classical Hodgkin Lymphoma;   HIV Infection;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vinblastine
18 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
19 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin hydrochloride;   Drug: vinblastine;   Drug: dacarbazine;   Procedure: quality-of-life assessment;   Genetic: DNA analysis;   Genetic: RNA analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: polymorphism analysis
20 Withdrawn Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years